The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Understanding inherited contributions to myeloma risk to improve risk stratification and treatment
In this video, Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, briefly comments on work highlighting the potential impact of dissecting inherited contributions to multiple myeloma (MM) risk. Dr Parekh outlines the need for a clear pathway to test patients and their family members for germline mutations associated with familial cancer to ensure appropriate counseling and treatment is provided. This could improve risk stratification and treatment outcomes for individuals with specific familial cancer mutations. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We frequently find patients coming to us in the clinic with a history of family members that have MGUS, multiple myeloma or other solid tumors and we don’t really have a clear answer for them or a pathway to test them and their family members.
Based on a new study that just came out in January by Santiago Thibaud, a colleague at my institution, we found in sequencing over 1,500 patients that about 8% of patients with myeloma have a germline mutation in a gene that is associated with familial cancer, and there needs to be a pathway for testing not just myeloma patients, but also their family members so that they can get the appropriate counseling and testing...
We frequently find patients coming to us in the clinic with a history of family members that have MGUS, multiple myeloma or other solid tumors and we don’t really have a clear answer for them or a pathway to test them and their family members.
Based on a new study that just came out in January by Santiago Thibaud, a colleague at my institution, we found in sequencing over 1,500 patients that about 8% of patients with myeloma have a germline mutation in a gene that is associated with familial cancer, and there needs to be a pathway for testing not just myeloma patients, but also their family members so that they can get the appropriate counseling and testing. In fact, Dr Thibaud also found that patients that have certain familial cancer mutations do better with alkylating agent therapy like autologous stem cell transplant. So this may have important therapeutic implications and these are just some of the new findings. They may be the tip of the iceberg in this whole field that is developing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
